ArticleDrug design, development and therapy2026
The Effect of AZD5153 on Radiosensitivity in Pancreatic Cancer Cells Through ATM-chk1 Pathway.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radioresistance compromises pancreatic cancer radiotherapy outcomes, making the identification of radiosensitizing strategies a critical priority. AZD5153, a novel specific Bromodomain-containing protein 4 (BRD4) inhibitor, has demonstrated efficacy in relapsed/refractory solid tumors and lymphomas. Our research focuses on investigating the effect of AZD5153 on the radiotherapy sensitivity of human pancreatic cancer cells, and its underlying mechanisms. Methods: CCK-8 was used to detect the effect of AZD5153 on pancreatic cancer cell proliferation activity. The radiosensitizing effect of AZD5153 was determined by cell colony formation assay. Fow cytometry, western blot and immunofluorescence were performed to analyze cell cycle, apoptosis and protein expression following AZD5153 and/or radiotherapy treatment in pancreatic cancer cells. A Capan2 pancreatic cancer xenograft mouse model was established to validate the radiosensitizing effect of AZD5153 in vivo. Results: AZD5153 showed the anti-proliferative effects on Capan2 and PANC1 cells and significantly enhanced radiosensitivity in both cell lines. The in vivo experiments also demonstrated that the combination of AZD5153 and radiotherapy enhanced anti-tumor efficacy relative to monotherapy. Moreover, AZD5153 alone or combined with radiation caused G2/M phase cell cycle arrest, and increased H2AX phosphorylation with γ-H2AX foci formation, indicating that AZD5153 enhanced radiotherapy-induced DNA damage in pancreatic cancer cells. Further molecular mechanism study revealed that AZD5153 inhibited radiotherapy-activated ATM-chk1 pathway, suggesting that AZD5153 may enhance radiosensitivity by impairing DNA damage repair. Conclusion: Collectively, these results suggested that AZD5153 might be a promising radiosensitizing agent, and targeting the ATM-chk1 pathway may offer a novel therapeutic strategy to overcome radioresistance in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.